A history of moderate to severe traumatic brain injury is associated with an increased risk of malignant brain tumors, data suggest.

The FDA is moving to abandon a decades-old policy of asking advisory committees to review drug applications, and critics say the move could shield the agency's decisions from public scrutiny.

Our findings continue to highlight the complex landscape of cancer care costs and call for further research and policy changes,” the researchers wrote.

It was difficult to determine the effect of bevacizumab on survival in this analysis because details on adjuvant therapy, maintenance therapy, and BRCA or HRD status were not available, the ...